Did You Know...
...that "patent leather" got its name because the process of applying the polished black finish to leather was once patented?
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7172892 | Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon Provided herein are polypeptides designated CVSP14 polypeptides that exhibit protease activity as a single chain or as an activated two chain form. Methods using the polypeptides to identify compounds that modulate the protease activity thereof are provided. The pol... | 02/06/2007 |
| 7160462 | Eluent for ion chromatography for measuring alkaline earth metal ions, and method for analyzing alkaline earth metal ions, employing it An eluent for ion chromatography for analyzing divalent cations, which comprises an acid and at least one amino acid selected from the group consisting of histidine, lysine and arginine. ... | 01/09/2007 |
| 7125703 | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon Provided herein are type II transmembrane serine protease 7 (MTSP7) polypeptides. Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided. Methods using the polypeptides to identify compounds t... | 10/24/2006 |
| 7112430 | Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon Provided herein are type II transmembrane serine protease 10 (MTSP10) polypeptides. Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided. Methods using the polypeptides to identify compounds... | 09/26/2006 |
| 7105333 | Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon Provided herein are type II transmembrane serine protease 9 (MTSP9) polypeptides. Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided. Methods using the polypeptides to identify compounds t... | 09/12/2006 |
| 7074401 | Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys300→His), perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while ... | 07/11/2006 |
| 7045280 | Assay method The present invention provides a method for the measurement of the activity of a plasminogen activator, such as urokinase plasminogen activator (uPA) or tissue plasminogen activator (tPA) in a biological sample using an assay method characterized by the inclusion of... | 05/16/2006 |
| 7041479 | Enhanced synthesis of active proteins containing disulfide bonds Compositions and methods are provided for the enhanced in vitro synthesis of polypeptides containing disulfide bonds. In order to improve the performance of in vitro protein synthesis reactions, pre-treatment and redox buffering of the reaction mix is performed in o... | 05/09/2006 |
| 7022673 | Method for increasing the serum half-life of a biologically active molecule A method is provided for preparing a biologically active molecule having an increased serum half-life. The method involves conjugating a polymer such as polyethylene glycol to the biologically active molecule. Also provided are polypeptide drugs having an increased ... | 04/04/2006 |
| 7001872 | Subterranean formation treating fluid and methods of fracturing subterranean formations The present invention relates to methods and compositions for treating subterranean well formations, and more specifically, to improved subterranean formation treating fluid concentrates, treating fluids and methods of using such treating fluids in subterranean form... | 02/21/2006 |
| 6967219 | Reversing or preventing premature vascular senescence Premature vascular senescence is reversed or prevented in tissue or cells by contacting the tissue or cells with a hydroxyguanidine. This finds application in treatment of patients with a disorder associated with elevated levels of advanced glycation end products in... | 11/22/2005 |
| 6964764 | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a... | 11/15/2005 |
| 6923895 | Coated capillary electrophoresis tubes and system The invention is directed to a capillary tube for electrophoresis that has a positively charged coating on the capillary inner surface that prevents positively charged analytes from adsorbing to the inner capillary surface. The capillary tube has an inner surface th... | 08/02/2005 |
| 6902884 | Method and tool for prognosticating HIV infection in a subject by measuring soluble urokinase plasminogen activator receptor, degradation products thereof, and urokinase plasminogen activator receptor Method of diagnosing and/or prognosticating HIV infection in a subject comprising the steps of: (a) performing in vitro a measurement of the level of a marker in the form of (i) urokinase plasminogen activator receptor (uPAR), (ii) soluble urokinase plasminogen acti... | 06/07/2005 |
| 6899877 | Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina A process for inhibiting vascular proliferation separately introduces components into the eye to generate plasmin in the eye in amounts to induce complete posterior vitreous detachment where the vitreoretinal interface is devoid of cortical vitreous remnants. The pr... | 05/31/2005 |
| 6884780 | Method for increasing the serum half-life of a biologically active molecule A method is provided for preparing a biologically active molecule having an increased serum half-life. The method involves conjugating a polymer such as polyethylene glycol to the biologically active molecule. Also provided are polypeptide drugs having an increased ... | 04/26/2005 |
| 6846656 | Process for producing N-acetylneuraminic acid The present invention provides a process for economically producing N-acetylneuraminic acid without using expensive materials such as pyruvic acid and phosphoenolpyruvic acid. The process comprises: allowing (i) a culture of a microorganism having N-acetylneuraminic... | 01/25/2005 |
| 6680174 | Assay for growth differentiation factor 9 The present invention relates to a method of identifying an agent which alters (inhibits, enhances) activity of GDF-9. The method involves combining cells having a receptor for GDF-9 and a gene, wherein expression of the gene is regulated by binding of GD... | 01/20/2004 |
| 6585972 | Process for crosslinking of collagen in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina A process for inhibiting vascular proliferation introduces a composition into the eye inducing posterior vitreous detachment. The composition includes a combination of plasminogen, a collagen crosslinking agent and at least one plasminogen activator selec... | 07/01/2003 |
| 6569636 | Assay for modulators of metallo-enzyme activity An assay is disclosed for determining whether a test compound modulates the activity of an enzyme having a metallated active site. The assay method employs a comparison of the binding ability of the metallated and unmetallated forms of the enzyme to the t... | 05/27/2003 |
| 6548276 | Enhanced in vitro synthesis of active proteins containing disulfide bonds Compositions and methods are provided for the enhanced in vitro synthesis of polypeptides containing disulfide bonds. In order to improve the performance of in vitro protein synthesis reactions, pre-treatment and redox buffering of the reaction mix is per... | 04/15/2003 |
| 6488927 | Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.... | 12/03/2002 |
| 6423685 | Method for increasing the serum half-life of a biologically active molecule A method is provided for preparing a biologically active molecule having an increased serum half-life. The method involves conjugating a polymer such as polyethylene glycol to the biologically active molecule. Also provided are polypeptide drugs having an... | 07/23/2002 |
| 6403556 | Pharmaceutical preparation containing protein C and a thrombolytically active substance A pharmaceutical preparation contains protein C and a thrombolytically active substance that does not activate protein C. This preparation prevents reocclusion usually occurring in the course of thrombolysis therapy.... | 06/11/2002 |
| 6355243 | Method of thrombolysis by local delivery of active plasmin The invention provides an improved method of thrombolytic therapy by the direct admiistration of active plasmin to a clot site via catheter. An active, stable preparation of plasmin is provided, as is a process for activation and isolation of active plasm... | 03/12/2002 |
| 6284475 | Assays for diagnosis of thrombophilic disease The present invention provides methods for diagnosing and/or monitoring thrombophilic disease in a patient that can result from the antiphospholipid antibody syndrome (aPL syndrome). The methods of the invention are premised on the inhibition of binding o... | 09/04/2001 |
| 6239106 | Family of protease inhibitors, and other biologic active substances The invention relates to novel protease-inhibitors which are obtainable from leeches. It also relates to uses thereof, for instance as a medicament, thus pharmaceutical preparations are provided, as are derivatives, mutants, genes encoding, vectors compri... | 05/29/2001 |
| 6190659 | Bacterial plasmin binding protein and methods of use thereof The present invention describes a novel polypeptide, and methods of its use in effective thrombolytic therapy in the treatment of coronary and pulmonary thrombosis. Its use is also disclosed in vaccines to abrogate a streptococcal infection. Pharmaceutica... | 02/20/2001 |
| 6120765 | Urokinase plasminogen activator fragments Purified uPA peptides having, mitogenic activity and containing as few as six amino acids of the EGF-like domain of uPA.... | 09/19/2000 |
| 6117652 | Production of proteins by cell culture Methods for enhancing the production of tissue plasminogen activator (tPA) in cell culture are disclosed. The methods involve culturing tPA-producing cells in growth media supplemented with an alkanoic acid or salt thereof at a concentration which enhance... | 09/12/2000 |
| 6113897 | Antibodies and their use A monoclonal or polyclonal antibody directed against urokinase plasminogen activator receptor (u-PAR), or a subsequence, analogue or glycosylation variant thereof. Antibodies are disclosed which react with free u-PAR or with complexes between u-PA and u-P... | 09/05/2000 |
| 6022854 | Platelet specific therapeutic compound and method of treating A therapeutic compound comprises a KGD-containing peptide, tandem repeats thereof, combinations thereof, or combinations thereof with an RGD-containing peptide or tandem repeats thereof, or peptide analogues or non-peptide organic analogues of the RGD and... | 02/08/2000 |
| 5976532 | Method of antithrombotic therapy using anti-GPIIb/IIIa antibodies or fragments thereof, including c7E3 Platelet-specific, chimeric immunoglobulin and immunoglobulin fragments are described. The chimeric molecules are made up of a nonhuman antigen binding region and a human constant region. Preferred immunoglobulins are specific for glycoprotein IIb/IIIa re... | 11/02/1999 |
| 5935789 | Autonomously replicating sequences, GAPDH gene and promoter derived from Hansenula polymorpha, expression vectors containing same and method for the selection of transformants Autonomously replicating sequences(ARS), glyceraldehyde-3-phosphate dehydrogenase(GAPDH) gene and GAPDH promoter derived from Hansenula polymorpha DL-1(ATCC 26012); a vector for H. polymorpha which contains the novel ARS and is capable of inserting tandem... | 08/10/1999 |
| 5880259 | Peptide useful as a ligand A peptide of formula (I) (H2 N--X1 --Thr--X2 --CO)n --R (I) where X1 and X2, different one another, are an amino acid residue of arginine or tyrosine in configuration L or D, wherein the hydr... | 03/09/1999 |
| 5866358 | Production of human prourokinase A method is provided for producing non-glycosylated single chain prourokinase (proUK). The method comprises cultivating bacterial strains of E. coli which have been transformed with plasmids carrying the cDNA sequence coding for proUK.... | 02/02/1999 |
| 5830467 | Pharmaceutical preparation containing protein C and a thrombolytically active substance A pharmaceutical preparation contains protein C and a thrombolytically active substance that does not activate protein C. This preparation prevents reocclusion usually occurring in the course of thrombolysis therapy.... | 11/03/1998 |
| 5811252 | Modified proenzymes as substrates for proteolytic enzymes Detection or determination of a protease in a sample by incubating the sample with a substrate of the protease and observing proteolytic cleavage of said substrate. The substrate is a modified proenzyme containing a recognition site, e.g., an activation s... | 09/22/1998 |
| 5770425 | Human tissue plasminogen activator variants Disclosed are novel variants of tissue plasminogen activator (t-PA) that have surprising biological/pharmacokinetic properties compared with native t-PA. For example, certain of the variants hereof demonstrate increased half-life profiles, and show good f... | 06/23/1998 |
| 5759542 | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases A fusion drug including an isolated portion of the A-chain of a urokinase-type plasminogen activator linked to a drug, wherein the A-chain portion binds stably to an outer membrane of a platelet. The T1/2 of the fusion drug in plasma is thereb... | 06/02/1998 |
